Penny Wise, Pound Foolish? Coverage Limits on Immunosuppression after Kidney Transplantation
- 16 February 2012
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 366 (7), 586-589
- https://doi.org/10.1056/nejmp1114394
Abstract
As a treatment for end-stage renal disease (ESRD), kidney transplantation is superior to dialysis for improving patient survival rates and quality of life. Its long-term success, however, requires ongoing treatment with immunosuppressive drugs. Ironically, although many of the pivotal discoveries related to immunosuppression have been made in the United States, U.S. kidney-transplant recipients do not benefit from a coherent funding policy for these drugs, and thousands of such patients are therefore at risk for allograft failure and premature death. Ensuring lifetime access to these medications for all Americans with kidney transplants would save lives as well as reduce the total cost of treating patients with ESRD.Keywords
This publication has 5 references indexed in Scilit:
- Cost-Related Immunosuppressive Medication Nonadherence Among Kidney Transplant RecipientsClinical Journal of the American Society of Nephrology, 2010
- A Conflict of ResponsibilityClinical Journal of the American Society of Nephrology, 2010
- Cost–effectiveness of Medicare’s coverage of immunosuppression medications for kidney transplant recipientsExpert Review of Pharmacoeconomics & Outcomes Research, 2009
- Income-Related Disparities in Kidney Transplant Graft Failures Are Eliminated by Medicare’s Immunosuppression CoverageAmerican Journal of Transplantation, 2008
- Payment for Immunosuppression After Organ TransplantationJAMA, 2000